RU2013138180A - Способы лечения макулярного отека с использованием противоотечных лекарственных средств - Google Patents

Способы лечения макулярного отека с использованием противоотечных лекарственных средств Download PDF

Info

Publication number
RU2013138180A
RU2013138180A RU2013138180/15A RU2013138180A RU2013138180A RU 2013138180 A RU2013138180 A RU 2013138180A RU 2013138180/15 A RU2013138180/15 A RU 2013138180/15A RU 2013138180 A RU2013138180 A RU 2013138180A RU 2013138180 A RU2013138180 A RU 2013138180A
Authority
RU
Russia
Prior art keywords
letters
months
patients
visual acuity
patient
Prior art date
Application number
RU2013138180/15A
Other languages
English (en)
Russian (ru)
Inventor
Пол Эштон
Original Assignee
Псивида Юэс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Псивида Юэс, Инк. filed Critical Псивида Юэс, Инк.
Publication of RU2013138180A publication Critical patent/RU2013138180A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2013138180/15A 2011-02-11 2012-02-13 Способы лечения макулярного отека с использованием противоотечных лекарственных средств RU2013138180A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161442151P 2011-02-11 2011-02-11
US61/442,151 2011-02-11
PCT/US2012/024910 WO2012109673A1 (en) 2011-02-11 2012-02-13 Methods of treating macular edema using antiedema therapeutics

Publications (1)

Publication Number Publication Date
RU2013138180A true RU2013138180A (ru) 2015-03-20

Family

ID=46637026

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013138180/15A RU2013138180A (ru) 2011-02-11 2012-02-13 Способы лечения макулярного отека с использованием противоотечных лекарственных средств

Country Status (8)

Country Link
US (1) US20120207682A1 (https=)
EP (1) EP2673049A4 (https=)
JP (1) JP2014508749A (https=)
CN (1) CN103402582A (https=)
AU (1) AU2012214146A1 (https=)
CA (1) CA2827082A1 (https=)
RU (1) RU2013138180A (https=)
WO (1) WO2012109673A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP2968882B1 (en) * 2013-03-12 2021-05-19 EyePoint Pharmaceuticals US, Inc. Drug delivery device comprising silicon-based carrier particles
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) * 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
SG10201809363SA (en) * 2013-11-15 2018-11-29 Allergan Inc Methods of treatment of ocular conditions with a sustained drug delivery implant
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EP4537830A3 (en) 2017-06-13 2025-06-11 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ575950A (en) * 2003-11-13 2010-06-25 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
WO2010129545A2 (en) * 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles

Also Published As

Publication number Publication date
AU2012214146A1 (en) 2013-08-29
CN103402582A (zh) 2013-11-20
EP2673049A4 (en) 2015-04-08
CA2827082A1 (en) 2012-08-16
US20120207682A1 (en) 2012-08-16
EP2673049A1 (en) 2013-12-18
JP2014508749A (ja) 2014-04-10
WO2012109673A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
RU2013138180A (ru) Способы лечения макулярного отека с использованием противоотечных лекарственных средств
JP2014508749A5 (https=)
Dutra Medeiros et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema
Jaffe et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results
Plontke et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy
Jaffe et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results
Whitcup et al. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis
Kuppermann et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema
Herrero-Vanrell et al. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema
Bratton et al. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis
US11622935B2 (en) Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles
CN101287423A (zh) 含药植入物及其使用方法
EA032183B1 (ru) Устройство для внутриглазной доставки лекарственного средства, способ его получения и способы его применения
JP2011518164A (ja) 生分解性材料中のデキサメタゾン配合物
JP2011518183A (ja) 液体製剤と組み合わせて製剤化した薬物デポー剤で急性疼痛を治療するための方法
CN110339153A (zh) 地塞米松单位剂型、试剂盒及白内障手术后炎症中的应用
Freeman Cystoid macular oedema in uveitis: an unsolved problem
Fisher et al. Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery
O’Brien Laramy et al. Long-acting ocular drug delivery technologies with clinical precedent
CN103637977A (zh) 含药植入物及其使用方法
Al Zamil Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema
JP2007532652A (ja) 黄斑浮腫患者の選択方法およびステロイドを含む眼のインプラントによる治療方法
JP2015526407A (ja) 増量剤を用いた失禁を安定的に治療する方法
JP2011513337A (ja) 椎間板ヘルニアを治療するための方法および組成物
Margines et al. Results of corneal collagen cross-linking in patients with corneal ectasia after laser refractive surgery—A prospective study

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20161213